Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-02

Study Completion Date

2020-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite its known prevalence in IBD, a recent study conducted with Prof. Cacoub (unpublished) on the national health insurance database showed that iron deficiency was an under-diagnosed and under-treated co-morbidity. In chronic diseases including IBD, Transferrin Saturation Factor is only performed in approximately 10% of cases, whereas it is recommended in inflammatory situations including IBD patients (HAS 2011).

The objective of this study is therefore to obtain updated French data on the prevalence of iron deficiency in patients with IBD by applying the recommendations of ECCO and French Health High Authority (determination of ferritinemia and Transferrin Saturation Factor)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease

NCT05456932

Inflammatory Bowel Diseases Iron-deficiency Iron Deficiency Anemia

UNKNOWN PHASE4

Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease

NCT05733845

Crohn's Disease Ulcerative Colitis

RECRUITING NA

Development of Inflammation and Fibrosis Index, Combining MRI and PET 18F-FDG, in Patient's With Crohn's Disease

NCT04467580

Crohn Disease

UNKNOWN NA

Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases

NCT02508012

Crohn's Disease Ulcerative Colitis

COMPLETED NA

Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.

NCT05581420

Inflammatory Bowel Diseases

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intestinal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBD

Group Type EXPERIMENTAL

Iron status testing

Intervention Type DIAGNOSTIC_TEST

Iron status testing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iron status testing

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient, male or female, over 18 years old
* Patient present at the hospital on the day of the study
* Diagnosis of IBD on international criteria
* Patient giving written consent

Exclusion Criteria

* Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision;
* pregnant, lactating or parturient woman;
* Patient hospitalized without consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No